tailieunhanh - Báo cáo y học: "Are we ready for therapeutic drug monitoring of biologic therapeutics"

Tuyển tập các báo cáo nghiên cứu về y học được đăng trên tạp chí y học General Psychiatry cung cấp cho các bạn kiến thức về ngành y đề tài: Are we ready for therapeutic drug monitoring of biologic therapeutics? | Krieckaert and Lems Arthritis Research Therapy 2011 13 120 http content 13 4 120 EDITORIAL L_ Are we ready for therapeutic drug monitoring of biologic therapeutics Charlotte LM Krieckaert 1 and Willem F Lems1 2 See related research by Ducourau etal. http content 13 3 R105 Abstract In the previous issue of Arthritis Research Therapy Ducourau and colleagues report that they retrospectively detected anti-infliximab antibodies in 21 of patients with rheumatic diseases. Patients with anti-infliximab antibodies had lower serum drug concentrations. These findings contribute to the existing evidence of immunogenicity of biologicals and its clinical relevance. We argue for therapeutic drug monitoring to optimize treatment response. Therapeutic drug monitoring seems to be an important new aspect in the treatment of patients with rheumatic diseases. This is argued by Ducourau and colleagues 1 in the previous issue of Arthritis Research Therapy. In a retrospective study of 17 patients with rheumatoid arthritis and 91 patients with spondyloarthritis the authors measured trough serum infliximab levels and antibodies toward infliximab at each visit. Antibodies against infliximab were detected in 21 patients 19 and the median detection time was months. In the larger group of patients with spondyloarthritis infliximab levels were only mg L in those with antibodies and mg L in those without antibodies P and the same pattern was found in the smaller rheumatoid arthritis group. In addition patients with antibodies used methotrexate less often and infusion reactions occurred more often in the antibody-positive patients 52 versus 1 . We believe that this is an adequately performed but retrospective study that does not show exciting new data but that does confirm the clinical relevance of measuring serum levels and anti-drug antibodies in patients treated with biologicals. Correspondence 1Jan